— Early sign of Alzheimer's reversed in lab — One of the earliest known impairments caused by Alzheimer's disease - loss of sense of smell - can be restored by removing a plaque-forming protein in a mouse model of the disease,…
— Parental controls on embryonic development? — When a sperm fertilises an egg, each contributes a set of chromosomes to the resulting embryo, which at these very early stages is called a zygote. Early on, zygotic genes are inert,…
— Newly discovered heart stem cells make muscle and bone — Researchers have identified a new and relatively abundant pool of stem cells in the heart. The findings in the December issue of Cell Stem Cell, a Cell Press publication, show that…
— BUSM researchers develop blood test to detect membranous nephropathy — Research conducted by a pair of physicians at Boston University School of Medicine (BUSM) and Boston Medical Centre (BMC) has led to the development of a test that can help diagnose…
— New hip implants no better than traditional implants — New hip implants appear to have no advantage over traditional implants, suggests a review of the evidence published on bmj.com today…
— Action needed to improve men's health in Europe — Policies aimed specifically at men are urgently needed to improve the health of Europe's men, say experts on bmj.com today…
— Probiotics reduce infections for patients in intensive care — Traumatic brain injury is associated with a profound suppression of the patient's ability to fight infection. At the same time the patient also often suffers hyper-inflammation, due…
— High blood sugar levels in older women linked to colorectal cancer — Elevated blood sugar levels are associated with an increased risk of colorectal cancer, according to a study led by researchers at Albert Einstein College of Medicine of Yeshiva University.…
— Engineered botulism toxins could have broader role in medicine — The most poisonous substance on Earth - already used medically in small doses to treat certain nerve disorders and facial wrinkles - could be re-engineered for an expanded role in helping…
Screening does not reduce prostate cancer deaths
Screening does not significantly reduce prostate cancer deaths, but the risk of overdetection and overtreatment is considerable, concludes a 20-year study published on bmj.com today.
Prostate cancer is one of the most common cancers among men worldwide. Screening is widely used in many countries, but remains controversial because experts can't agree whether the benefits outweigh the potential harms and costs of overdiagnosis and overtreatment of healthy men.
Today's findings are based on a trial started in Sweden in 1987 involving 9,026 men aged 50-69 years identified in the National Population Register.
From this population, 1,494 men were randomly selected for screening every third year from 1987 to 1996. The remaining 7,532 men acted as controls.
On the first two occasions, screening was done by digital rectal examination only. From 1993, this was combined with prostate specific antigen (PSA) testing. On the fourth occasion (1996), only men aged 69 or under at the time of the investigation were invited.
All men with cancer diagnosed up to December 31, 1999 were included in the analysis. Survival was followed until December 31, 2008.
There were 85 cases (5.7%) of prostate cancer diagnosed in the screened group and 292 (3.9%) in the control group. The tumours in the screening group were smaller and more often localised than in the control group.
Analysis did not show significantly longer survival or overall survival for men with prostate cancer in the screened group compared with the control group.
And while screening and treating men with detected tumours might reduce deaths specifically from prostate cancer by up to a third (at best), this would be at considerable risk of worrying overdetection and unpleasant or harmful overtreatment. Indeed, a previous trial found that to prevent one death from prostate cancer, 1,410 men would need to be screened and 48 treated.
The authors believe that men should be fully informed about the potential hazards of treatment, and the psychological effects of false-positive test results, before they are screened.
They also argue that the next goal for prostate screening should be to find ways of discriminating slow-growing (indolent) tumours from high risk tumours and to develop less aggressive treatment for indolent tumours, rather than to optimise sensitivity of the diagnostic tests.
'After 20 years of follow-up, the rate of death from prostate cancer did not differ significantly between men in the screening group and those in the control group,' they conclude. Results from randomised controlled trials of prostate cancer screening have been published in recent years, but none with 20 years of follow-up, they add. Long follow-up is necessary to draw definite conclusions about the benefits of screening.
Or subscribe for our Newsletter, a free e-mail publication. It is published practically every day.
Protein's essential role in repairing damaged cells revealed
Researchers at the Salk Institute develop novel glioblastoma mouse model
Can Nintendo Wii game consoles improve family fitness?
Patient-derived induced stem cells retain disease traits